生物信息红外肝病治疗仪联合富马酸丙酚替诺福韦用于乙肝病毒致急慢性肝衰竭患者的临床疗效  

Clinical efficacy of bioinformatics infrared liver disease therapeutic instrument combined with propofol tenofovir fumarate in patients with acute and chronic liver failure caused by hepatitis B virus

作　　者：刘家欣 Liu Jiaxin(Tianjin Third Central Hospital,Tianjin 300170,China)

机构地区：[1]天津市第三中心医院,天津300170

出　　处：《首都食品与医药》2025年第1期42-45,共4页Capital Food Medicine

摘　　要：目的探究生物信息红外肝病治疗仪联合富马酸丙酚替诺福韦用于HBV致急慢性肝衰竭患者的临床疗效。方法选取天津市第三中心医院2022年7月-2023年7月收治的120例乙肝病毒致急慢性肝衰竭患者,使用抽签法分组(对照组、观察组),每组各60例。对照组予以富马酸丙酚替诺福韦治疗,观察组在此基础上予以生物信息红外肝病治疗仪。对比两组肝功能相关生化指标、乙肝病毒的脱氧核糖核酸(HBV DNA)复制水平、外周血细胞计数、乙型肝炎E抗原(HBeAg)转阴率。结果治疗后,观察组总胆红素(TBIL)、丙氨酸氨基转移酶(ALT)、国际标准化比值(INR)低于对照组,白蛋白(ALB)高于对照组(P<0.05)。治疗后,观察组白细胞计数(WBC)、中性粒细胞百分比(NEU)低于对照组,血红蛋白浓度(HGB)、血小板计数(PLT)高于对照组(P<0.05)。治疗后,观察组HBV DNA复制水平低于对照组,HBeAg转阴率为66.67%,较对照组的46.67%高(P<0.05)。结论HBV致急慢性肝衰竭患者使用富马酸丙酚替诺福韦联合生物信息红外肝病治疗仪治疗,有助于改善患者肝脏功能,降低HBV DNA的复制水平,疗效显著,值得临床推广。Objective To investigate the clinical efficacy of a bioinformatics infrared liver disease treatment device combined with propafenone fumarate in patients with HBV induced acute and chronic liver failure.Methods 120 patients with acute and chronic liver failure caused by hepatitis B virus who were admitted to Tianjin Third Central Hospital from July 2022 to July 2023 were selected and divided into control group and observation group by lot drawing(60 cases in each group).The control group was given propafenone fumarate,while the observation group was given a bioinformatics infrared liver disease treatment device on this basis.The biochemical indexes related to liver function,replication level of hepatitis B virus deoxyribonucleic acid(HBV DNA),peripheral blood cell count,and negative rate of hepatitis B E antigen(HBeAg)were compared between the two groups.Results After treatment,the total bilirubin(TBIL),alanine aminotransferase(ALT),and international normalized ratio(INR)in the observation group were lower than those in the control group,while albumin(ALB)was higher than that in the control group(P<0.05).After treatment,the white blood cell count(WBC)and neutrophil percentage(NEU)in the observation group were lower than those in the control group,while the hemoglobin concentration(HGB)and platelet count(PLT)were higher than those in the control group(P<0.05).After treatment,the HBV DNA replication level in the observation group was lower than that in the control group,and the HBeAg conversion rate was 66.67%,which was higher than 46.67%in the control group(P<0.05).Conclusion The use of propafenone fumarate and bioinformatics infrared liver disease treatment device in patients with acute and chronic liver failure caused by HBV can improve liver function and reduce HBV DNA replication levels.The clinical efficacy is significant and worthy of clinical promotion.

关 键 词：乙肝病毒 急慢性肝衰竭 富马酸丙酚替诺福韦 

分 类 号：R512.62[医药卫生—内科学]